

Johnson & Johnson Innovative Medicine Pipeline

Key Events in 2025*

POTENTIAL APPROVALS US/EU

✓ ✓	US EU	SIMPONI (golimumab) Pediatric Ulcerative Colitis (PURSUIT 2)
✓	EU	STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)
✓ ✓	US EU	TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)
✓ ✓	US EU	TREMFYA (guselkumab) Crohn's Disease Subcutaneous Induction (GRAVITI)
✓	US	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)
✓	US	TREMFYA (guselkumab) Pediatric Juvenile Psoriatic Arthritis
✓ ✓	US EU	TREMFYA (guselkumab) Crohn's Disease (GALAXI)
✓	EU	TREMFYA (guselkumab) Ulcerative Colitis (QUASAR)
✓	US	IMAAVY (nipocalimab) Generalized Myasthenia Gravis (Vivacity MG3)
✓	US	SPRAVATO (esketamine) Treatment Resistant Depression monotherapy (TRD4005)
✓	US	CAPLYTA (lumateperone) Adjunctive Treatment for Major Depressive Disorder
✓	US	DARZALEX (daratumumab) Smoldering Multiple Myeloma (AQUILA)
✓	US	DARZALEX (daratumumab) Frontline multiple myeloma transplant ineligible (CEPHEUS)
✓	US	INLEXZO (gemcitabine intravesical delivery system) Non Muscle Invasive Bladder Cancer (SunRISe-1)
✓	US	RYBREVENT (amivantamab) Subcutaneous (PALOMA-3)
✓	EU	IMBRUVICA (ibrutinib) Frontline MCL (Triangle)
✓	US	IMAAVY (nipocalimab) Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)
✓	US	AKEEGA (niraparib/abiraterone) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

PLANNED SUBMISSIONS US/EU

US	nipocalimab Warm Autoimmune Hemolytic Anemia (ENERGY)	✓	US	delivery system) Non Muscle Invasive Bladder Cancer (SunRISe-1)	
✓	EU	TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)	✓	US	AKEEGA (niraparib/abiraterone)
			✓	EU	M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)
✓	US	TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)	✓	US	TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3)
✓	EU	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)			
✓	US	STELARA (ustekinumab)			
✓	EU	Pediatric Ulcerative Colitis (UNIFI JR)			
✓	US	STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)			
✓	US	icotrokinra			
✓	EU	Psoriasis (ICONIC)			

POTENTIAL CLINICAL DATA PRESENTATIONS'

Phase III

✓	AKEEGA (niraparib/abiraterone) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)
✓	RYBREVENT / LAZCLUZE Non Small Cell Lung Cancer (MARIPOSA Final OS)
✓	TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)
✓	TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)
✓	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)
✓	icotrokinra Psoriasis (ICONIC-LEAD)
✓	icotrokinra Psoriasis (ICONIC-TOTAL)
✓	icotrokinra Psoriasis (ICONIC-Advance1/2)
✓	aticaprant Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1)
✓	RPGR Gene Therapy Retinitis Pigmentosa (LUMEOS)
✓	TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3)

Phase I/ II

✓	INLEXZO (gemcitabine delivery intravesical system) Non Muscle Invasive Bladder Cancer (SunRISe-1)
✓	RYBREVENT (amivantamab) Head and Neck Cancer (ORIGAMI-4)
✓	TALVEY + TECVAYLI Multiple Myeloma Relapsed/Refractory (RedirectT-1)
✓	JNJ-4496 Hematological Malignancies (LYM1001)
✓	JNJ-5322 Multiple Myeloma (MMY1001)
✓	RYBREVENT (amivantamab) Colorectal Cancer (ORIGAMI-1 right-sided)
✓	JNJ-8343 Prostate Cancer (PCR1001)
✓	JNJ-4804 Co-antibody Therapy Psoriatic Arthritis (AFFINITY)
✓	icotrokinra Ulcerative Colitis (ANTHEM)

✓ = Achieved



In order to be on key events clinical presentation, data must be presented at a major medical meeting.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of January 21, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.